drugset / Trial / NCT00183742
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Phase 1
Completed
35 enrolled
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.
Timeline
- Start
- 2000-12
- Primary completion
- 2005-10
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |